CSIMarket
 
Intellia Therapeutics Inc   (NTLA)
Other Ticker:  
 
 
Price: $28.3000 $0.78 2.834%
Day's High: $28.32 Week Perf: -4.2 %
Day's Low: $ 27.41 30 Day Perf: 0.07 %
Volume (M): 2,031 52 Wk High: $ 47.48
Volume (M$): $ 57,489 52 Wk Avg: $34.37
Open: $27.41 52 Wk Low: $22.67



 Market Capitalization (Millions $) 2,509
 Shares Outstanding (Millions) 89
 Employees -
 Revenues (TTM) (Millions $) 52
 Net Income (TTM) (Millions $) -462
 Cash Flow (TTM) (Millions $) -354
 Capital Exp. (TTM) (Millions $) 12

Intellia Therapeutics Inc
Intellia Therapeutics Inc is a biotechnology company that focuses on developing therapeutic products based on the revolutionary CRISPR gene editing technology. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts. Intellia aims to utilize CRISPR technology to develop potential cures for genetic diseases by editing and correcting specific genes within the human body. They are also involved in precision oncology, where they aim to develop targeted therapies for various types of cancers. Intellia Therapeutics is known for its innovative research and collaboration with other leading institutions in the field of gene editing.


   Company Address: 40 Erie Street Cambridge 2139 MA
   Company Phone Number: 285-6200   Stock Exchange / Ticker: NASDAQ NTLA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

The Phase 3 MAGNITUDE Study of NTLA-2001: A Promising CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

Published Mon, Mar 18 2024 11:30 AM UTC

Intellia Therapeutics, a renowned clinical-stage gene editing company, has recently commenced the global pivotal, Phase 3 MAGNITUDE trial of their investigational therapy, NTLA-2001. This single-dose, in vivo CRISPR-based treatment aims to inactivate the TTR gene, thereby preventing the production of TTR protein in patients with transthyretin (ATTR) amyloidosis with cardiomy...

Partnership

Evolving Cystic Fibrosis Treatment: Intellia Therapeutics and ReCode Therapeutics Partner to Develop Pioneering Gene Editing Therapies

Published Thu, Feb 15 2024 12:30 PM UTC

Intellia Therapeutics and ReCode Therapeutics Collaborate to Develop Groundbreaking Gene Editing Therapies for Cystic FibrosisIntellia Therapeutics, a prominent gene editing company, and ReCode Therapeutics, a genetic medicines company, have announced a strategic collaboration to develop innovative genomic medicines for the treatment of cystic fibrosis (CF). This partnership...

Clinical Study

NTLA-2002: A Promising CRISPR-Based Gene Editing Therapy for Hereditary Angioedema as Shown in Interim Phase 1 Results.

Published Wed, Jan 31 2024 10:00 PM UTC

Gene Editing Therapy Shows Promising Results in Hereditary Angioedema Patients: A Breakthrough Publication in The field of gene editing has witnessed a significant revolution in recent years, with the development of clustered regularly interspaced short palindromic repeats (CRISPR) technology. Intellia Therapeutics, a renowned clinical-stage gene editing company, has recentl...

Intellia Therapeutics Inc

NTLA's Fiscal Performance Reveals Alarming Evanescence of Diminishing Returns

Intellia Therapeutics Inc Faces Revenue Challenges in Recent Fiscal Period
Intellia Therapeutics Inc, a leading company in the In Vitro & In Vivo Diagnostic Substances sector, experienced a significant decrease in revenue and an increased deficit in its most recent fiscal period. The company recorded a loss per share of $-1.38, a slight improvement from the previous period's $-1.40 per share. However, revenue plummeted by -9.603% year on year, reaching $11.99 million compared to the previous year's $13.59 million.
This decline in revenue can be attributed to lower orders, which have led to a vanishing revenue and higher deficit for Intellia Therapeutics Inc. The situation raises concerns among investors as the company experiences a decline in performance.

Intellia Therapeutics Inc

Intellia Therapeutics Brushes Off 3.108% Q2 Revenue Dip Amidst Challenging Earnings Season in 2023


Introduction
Intellia Therapeutics Inc, a leading biotechnology company specializing in the development of gene-editing therapies, recently released its financial results for the April to June 30, 2023, period. The company witnessed a decline in revenue, resulting in losses compared to the previous year. This article examines the financial results in the context of market performance and provides an overview of Intellia Therapeutics' current status.
Decline in Revenue and Increased Shortfall
During the Q2 2023 financial period, Intellia Therapeutics Inc experienced lower revenue, with a decline of 3.108% amounting to $13.59 million. This drop in revenue resulted in a net shortfall of $-123.681 million, compared to $-100.678 million during the same period a year ago.






 

Intellia Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com